$1,444.80+1.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Lilly discovers, makes, and sells prescription medicines for diseases including diabetes, obesity, cancer, and inflammatory conditions.
Company outlook: revenue of $91B to $92B for Fiscal year 2026 — up 40.4% on a year earlier
Just reported
From ELI Lilly & Co's results release of October 29, 2026; its quarterly report has since been filed.
Actual
$24.4B
+39% y/y
+6.2% q/q
Guided
—
No guide given
Actual
$7.22
+16% y/y
-9.1% q/q
Guided
—
No guide given
Full year 2026
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $24.4B | $17.6B | +38.61% |
| Profit | $6.5B | $5.6B | +15.55% |
| Profit per share | $7.22 | $6.21 | +16.26% |
| Free Cash Flow | $8.2B | $6.7B | +21.80% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
A short summary of each call — what the quarter showed, what management expects and whether they delivered on what they said last time — with the full transcript underneath.
“Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to en sure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news. F-LLY 7
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from ELI Lilly & Co’s Item 2.02 8-K filed October 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
Call summaries are part of Pro
A two-minute read of every ELI Lilly & Co earnings call: the numbers that mattered, what management expects, whether they delivered on last quarter’s outlook, and what analysts asked that went unanswered.
See one first on , , , or — open to everyone.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Results released October 29, 2026, before the market closed
Shares jumped as Lilly lifted 2026 revenue expectations on volume-led growth, while acquisition charges and price declines tempered the earnings outlook.
Into the report: +8.8% over a month, +11.7% over three months, -1.4% from the year's high.
What the full-year guide leaves · Earnings per Share
Like for like: No adjusted-definition change is identified; performance-margin guidance rose from 49.0%–50.5% in the August 2026 release to 52.0%–52.5% in the October 2026 release.
Written by AI on October 30, 2026 from ELI Lilly & Co's results releases, earnings call and SEC filings; every quote it relied on was checked against them. It describes the report, it is not investment advice, and it is in English only.